Acquisitions and Collaborative Agreements (Biocon Insulin Products) (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013 Biocon Insulin Products Strategic Collaboration	Feb. 12, 2013 Biocon Insulin Products Strategic Collaboration Insulin analog drugs
Business Acquisition [Line Items]
Number of products						3
Research and development expense	$ 113,995	$ 108,250	$ 351,914	$ 283,570	$ 20,000

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References+ Details